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AF-MSCs fate can be regulated by culture conditions
DS Zagoura1,2,5, O Trohatou1,2,5, V Bitsika1,3, M Makridakis3, KI Pappa4, A Vlahou3, MG Roubelakis*,1,2,6 and NP Anagnou1,2,6
Human mesenchymal stem cells (hMSCs) represent a population of multipotent adherent cells able to differentiate into many
lineages. In our previous studies, we isolated and expanded fetal MSCs from second-trimester amniotic fluid (AF) and
characterized them based on their phenotype, pluripotency and proteomic profile. In the present study, we investigated the
plasticity of these cells based on their differentiation, dedifferentiation and transdifferentiation potential in vitro. To this end,
adipocyte-like cells (AL cells) derived from AF-MSCs can regain, under certain culture conditions, a more primitive phenotype
through the process of dedifferentiation. Dedifferentiated AL cells derived from AF-MSCs (DAF-MSCs), gradually lost the
expression of adipogenic markers and obtained similar morphology and differentiation potential to AF-MSCs, together with
regaining the pluripotency marker expression. Moreover, a comparative proteomic analysis of AF-MSCs, AL cells and DAF-MSCs
revealed 31 differentially expressed proteins among the three cell populations. Proteins, such as vimentin, galectin-1
and prohibitin that have a significant role in stem cell regulatory mechanisms, were expressed in higher levels in AF-MSCs and
DAF-MSCs compared with AL cells. We next investigated whether AL cells could transdifferentiate into hepatocyte-like cells
(HL cells) directly or through a dedifferentiation step. AL cells were cultured in hepatogenic medium and 4 days later they
obtained a phenotype similar to AF-MSCs, and were termed as transdifferentiated AF-MSCs (TRAF-MSCs). This finding, together
with the increase in pluripotency marker expression, indicated the adaption of a more primitive phenotype before
transdifferentiation. Additionally, we observed that AF-, DAF- and TRAF-MSCs displayed similar clonogenic potential, secretome
and proteome profile. Considering the easy access to this fetal cell source, the plasticity of AF-MSCs and their potential to
dedifferentiate and transdifferentiate, AF may provide a valuable tool for cell therapy and tissue engineering applications.
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Humanmesenchymal stem cells (hMSCs) have been isolated
from adult tissues, such as bone marrow (BM)1,2 and adipose
tissue3 as well as from fetal sources, including amniotic fluid
(AF),4–7 Wharton’s jelly8 and umbilical cord blood.9,10 MSCs
are multipotent cells capable of generating osteogenic,
adipogenic and chondrogenic cells in response to specific
culture conditions in vitro.1,4,6,7,11,12
Recently, our group has identified and studied MSCs from
human second-trimester AF, obtained during routine amnio-
centeses for prenatal diagnosis.6,7 The AF-MSC population is
gaining attention with regard of belonging to an intermediate
developmental stage between embryonic and adult stem
cells.4–7,13 Interestingly, AF-MSCs appear to express pluri-
potency markers such as Sox-2, Oct-4 and Nanog.6,7,13 We
documented that these cells exhibited high proliferation rate in
culture, were karyotypically stable when cultured ex vivo and
differentiated in vitro not only into cell types derived from
mesoderm but also into endoderm-derived cells, such as
hepatocytes.6,7,12 This multipotential differentiation capability
of AF-MSCs can be utilized for giving rise to a variety of
differentiated cell types for tissue repair and regeneration.4,12
To this end, we have recently shown the therapeutic effect of
AF-MSCs and hepatic progenitors, derived from AF-MSCs, in
CCl4 acute hepatic failure mouse model, and have investi-
gated the mechanism of their action at the site of injury12
without generating teratomas in vivo.4,5,12
During differentiation process, culture conditions, including
specific growth factors, cytokines and extracellular matrix
components, may have an important role in the determination
of the stem cell fate by switching from the self-renewal to a
differentiation stage and vice versa.11,14,15 This may happen
through various processes including dedifferentiation or
transdifferentiation.11 During dedifferentiation a terminally
differentiated cell returns to a more primitive state, whereas
the term transdifferentiation describes the process where a
fully differentiated cell acquires characteristics of other cell
types by switching its phenotype.11,16 Several studies have
documented that during dedifferentiation a downregulation of
1Laboratory of Biology, University of Athens School of Medicine, Athens, Greece; 2Cell and Gene Therapy Laboratory, Centre of Basic Research II, Biomedical Research
Foundation of the Academy of Athens (BRFAA), Athens, Greece; 3Biotechnology Laboratory, Centre of Basic Research, Biomedical Research Foundation of the
Academy of Athens (BRFAA), Athens, Greece and 4First Department of Obstetrics and Gynecology, University of Athens School of Medicine, Athens, Greece
*Corresponding author: MG Roubelakis, Laboratory of Biology, Medical School, University of Athens, Athens 115 27, Athens 115 27, Greece
Tel: þ 30 210 7462 145, þ 30 210 6597 013; Fax: þ 30 210 6597 545; E-mail: roubel@med.uoa.gr or mroubelaki@bioacademy.gr
5Joint first authors.
6Joint Senior Authors.
Received 02.10.12; revised 04.2.13; accepted 20.2.13; Edited by Y Shi
Keywords: AF-MSCs; differentiation; dedifferentiation; transdifferentiation; culture conditions
Abbreviations: hMSCs, human mesenchymal stem cells; AF, Amniotic fluid; AF-MSCs, mesenchymal stem cells derived from amniotic fluid; DAF-MSCs,
dedifferentiated AF-MSCs; TRAF-MSCs, transdifferentiated AF-MSCs; AL cells, adipocyte-like cells; OL cells, osteocyte-like cells; HL cells, hepatocyte-like cells; SSEA-4,
stage-specific embryonic antigen 4; Sox-2, SRY-sex determination SRY region Y-box2; Oct-4, octamer-binding transcription factor 4; Nanog, homeobox transcription
factor Nanog
Citation: Cell Death and Disease (2013) 4, e571; doi:10.1038/cddis.2013.93
& 2013 Macmillan Publishers Limited All rights reserved 2041-4889/13
www.nature.com/cddis
lineage-specific genes and an upregulation of stemness
genes occur, which is evident for the regaining of stem cell
phenotype.14,17,18 On the other hand, it has been demon-
strated that transdifferentiation capability of hMSCs is related
either to cell heterogeneity or cell fusion.11 More importantly,
cell-based therapy has been focused on the investigation of
the processes of dedifferentiation and transdifferentiation as
potential therapeutic strategies.16
The fetal origin and the unique characteristics of AF-MSCs
make them an advantageous mesenchymal stem cell
population for studying the cellular and molecular mecha-
nisms that are activated during the process of differentiation.
In the present study, we have developed an in vitro
differentiation system to analyze the cellular and molecular
events involved during the processes of differentiation,
dedifferentiation and transdifferentiation of AF-MSCs. Herein,
we attempt to answer two fundamental questions: (a) whether
in vitro differentiation is reversible and (b) whether committed
progenitors derived from AF-MSCs can switch their pheno-
type to another cell type directly or through a more primitive
phenotype.
Results
AL cells, derived from AF-MSCs, are able to dediffer-
entiate into a more primitive cell type. In the present
study, cell pellets from six second-trimester human
AF samples were plated according to previous protocols.6,7
Plastic-adherent colonies of AF-MSCs began to appear 8–12
days after the initial plating. Then, spindle-shaped (SS)
AF-MSCs were isolated and further expanded up to 40–50
passages with normal karyotype and high proliferation
capacity.6,7,12,19 AF-MSCs were tested for MSC marker
expression and were positive for CD73, CD90, CD105 and
CD166 antigens as well HLA-ABC, but not for the hemato-
poietic marker CD45 and the HLA-DR antigen.6,7,12,19
Previously, it has been reported that AF-MSCs were able to
differentiate into adipocytes, osteocytes, chondrocytes, hepa-
tocytes and neurocytes, representing in this way cell types
originating from all three germ layers.6,7,12 Indeed, after 2
weeks in culture in adipogenic medium, AF-MSCs exhibited
some typical characteristics of cultured adipocytes, and thus
were termed as adipocyte-like cells (AL cells).6
Initially, we assessed whether AL cells derived from
AF-MSCs could dedifferentiate to a more primitive stem cell-
like stage. As previously reported, AF-MSCs express embryo-
nic-related stem cell markers, such as stage-specific embryo-
nic antigen 4 (SSEA-4), SRY-sex determination SRY region
Y-box2 (Sox-2), octamer-binding transcription factor 4 (Oct-4)
and homeobox transcription factor Nanog.6,7 It was observed
that during adipogenic induction of AF-MSCs, SSEA-4, Sox-2,
Oct-4 and Nanog expression levels were gradually decreased
after 2 weeks in adipogenic medium (Figure 1a i). For this
reason, the expression of the embryonic stem cell-related
markers were examined at different time points during the
dedifferentiation process of AL cells into an uncommitted cell
type. For dedifferentiation studies, AL cells were divided into
three groups. One group was cultured in AF-MSC medium for
1 week, whereas the second and the third groupwere placed in
culture in AF-MSC medium for 2 and 3 weeks, respectively.
Interestingly, AL cells cultured in AF-MSC medium for 2
weeks exhibited similar expression levels of SSEA-4 (perce-
ntage of SSEA-4 expression, 72.49±8.41) to AF-MSCs
(percentage of SSEA-4 expression, 82.69±13.89; Figure 1a
ii). In addition, the pluripotency markers Sox-2 (P¼ 0.938,
Student’s t-test), Oct-4 (P¼ 0.064, Student’s t-test) and
Nanog (P¼ 0.184, Student’s t-test) were expressed in similar
levels in AF-MSCs and AL cells that have been cultured in
AF-MSCmedium for 2 weeks (Figure 1a ii). At this stage, cells
were termed as dedifferentiated AF-MSCs (DAF-MSCs).
DAF-MSCs showed higher expression levels for Oct-4,
Sox-2 and Nanog compared with AL cells, documenting a
more primitive phenotype of these cells (Figure 1a). Their
phenotype was altered to fibroblast-like and lost their ability to
form small lipid droplets, positive for Oil Red O staining
(Figure 1b). Additionally, DAF-MSCs exhibited lower levels of
expression for adipogenic markers, such as peroxisome
proliferator-activated receptor-g (PPARg) and lipoprotein
lipase (LPL) compared with AL cells (Figure 1c).
Comparison of the mitochondrial mass and lysosomal
activity in AF-MSCs, AL cells and DAF-MSCs was performed
by staining the cells with either MitoTracker or LysoTracker
fluorescent dyes (Molecular Probes Inc., Eugene, OR, USA;
Figure 2a). MSCs exhibited decreased mitochondrial tracker
dye/lysosome tracker dye ratio upon transitioning from the
stem cell to the differentiated state, implying a possible
alteration in the lysosomal activity.20,21 Thus, the ratio of
mitochondrial to lysosomal fluorescence was higher in
AF-MSCs (1.316±0.24) and DAF-MSCs (1.58±0.51) com-
pared with AL cells (0.602±0.071) (Figure 2b). In addition,
DAF-MSCs were still able to further differentiate under
appropriate culture conditions into AL, osteocyte-like (OL)
and hepatocyte-like cells (HL) (Supplementary Figure 1a).
Differentially expressed proteins in AF-MSCs, DAF-
MSCs and AL cells. A comparison of the proteome profile
of AF-MSCs, AL cells and DAF-MSCs was conducted,
following their separation by 2 DE on pH range of 4–7 linear
strips and mass spectrometry (MS; Figure 3a). At least three
gels per category were included in the analysis and
representative gel images are shown in Figure 3a. Thirty
one proteins were identified as differentially expressed (over
1.5-fold and Po0.05, Student’s t-test; Supplementary
Table 2). More particularly, a number of proteins was
identified in AF-MSCs only, including 14-3-3 protein b/a,
nucleoside diphosphate kinase A (NDKA) and tubulin-b chain
5 (TUBB), whereas collagen a-1(I) chain (COL1A1) and
dihydrolipoyllysine-residue succinyltransferase (DLST) were
present in DAF-MSCs and AL cells only, respectively
(Supplementary Table 3). On the other hand, specific
proteins were downregulated in AF-MSCs and DAF-MSCs
in comparison with AL cells, such as galectin-1 (LEG-1)
(Figure 3b i), which has an important role in cell differentia-
tion22 and prohibitin (PHB) (Figure 3b ii), a key molecule in
mitochondrial function, cell proliferation and development.23
However, eukaryotic translation initiation factor-3 (EIF3I)24
(Figure 3b iii) (Supplementary Table 2) was upregulated in
AF-MSCs and DAF-MSCs compared with AL cells. More
interestingly, protein, such as vimentin (VIME; Figure 3b iv),
which has a specific role in cell attachment, migration and
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Figure 1 Dedifferentiation potential of AL cells. (a) (i) SSEA-4 expression levels were examined by FACS analysis, and Sox-2, Oct-4 and Nanog expression levels by
Real-time PCR analysis genes during adipogenic induction of AF-MSCs. (ii) AF-MSCs and DAF-MSCs induced at different time points were analyzed for the expression of
SSEA-4 by FACS analysis and for the expression of Sox-2, Oct-4 and Nanog by real-time PCR analysis. Data are presented as the mean±S.D. of three independent
experiments, and were statistically analyzed by one-way ANOVA. (b) (i) Morphology of AF-MSCs, AL cells and DAF-MSCs in culture, and (b) (ii) after Oil Red O staining.
(c) Semiquantitative PCR analysis for PPARg and LPL on AF-MSCs, AL cells and DAF-MSCs. Data are presented as the mean±S.D. of three independent experiments and
were statistically analyzed by one-way ANOVA
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signaling,25 was identified in AF-MSCs and DAF-MSCs only.
Similarly, proteins with a regulatory role in protein synthesis
such as, ATP synthase (ATPB; Figure 3b v), reticulocalbin-3
(RCN3)26 (Figure 3b vi), protein disulfide-isomerase
(PDIA1)27 (Figure 3b vii) and the metabolic protein
glutathione S-transferase P1 (GSTP1; Figure 3b viii) were
also identified in AF-MSCs and DAF-MSCs, suggesting that
these two cell types were exhibiting a similar proteomic profile.
In order to verify the two-dimensional gel electrophoresis
(2DE) results, western blotting analysis was performed for
GSTP1 and PHB proteins. Bands of 32 and 26 kDa,
corresponding to GSTP1 and PHB proteins, respectively,
were detected in similar expression levels in AF-MSCs and
DAF-MSCs (Figure 3c).
AL cells, derived from AF-MSCs, were capable to
transdifferentiate into HL cells through a more primitive
cell type. We further examined whether transdifferentiation
of AL cells into HL cells happens directly or through the
process of dedifferentiation, into a more primitive phenotype
(Figure 4a). For this reason, AL cells were induced to
hepatogenesis for 21 days. The transdifferentiation process
was evaluated by Oct-4 expression analysis at different time
points. An increase in the expression of Oct-4 was detected
after the 4th day in hepatogenic medium (fold expression
difference: 0.19±0.04) compared with AL cells (fold expres-
sion difference: 0.07±0.01), suggesting that cells before
differentiating into HL cells, may return to an uncommitted
developmental stage (Supplementary Figure 2). Cells at this
stage (4th day) exhibited a spindle-shaped morphology and
were termed as transdifferentiated AF-MSCs (TRAF-MSCs;
Figure 4b i). Functional analysis revealed that only a small
percentage of TRAF-MSCs (11.1%±6.2) were positive
for Oil Red O staining versus AL cells (43.2%±12.11;
Figure 4b I, ii). Additionally, only few TRAF-MSCs were able
to store glycogen (6.75%±2.87) and uptake low-density
lipoprotein (LDL; 2.2±0.75, fluorescence intensity), com-
pared with HL cells (32%±6.48 for glycogen storage and
15.6±3.3 fluorescence intensity for LDL uptake; Figure 4b iii,
iv). Notably, TRAF-MSCs were still able to further differenti-
ate, under appropriate culture conditions into AL and OL cells
(Supplementary Figure 1B).
TRAF-MSCs exhibited similar characteristics to
AF-MSCs. To obtain further insight into the changes in the
gene expression profile during transdifferentiation, we
performed a comparative analysis for the pluripotency
markers Oct-4, Sox-2 and Nanog in TRAF-MSCs, AF-MSCs,
AL and HL cells by Real-time PCR analysis. AF-MSCs and
TRAF-MSCs exhibited higher levels of expression for Oct-4,
Sox-2 and Nanog compared with AL and HL cells,
documenting the primitive phenotype of the former cells
(Figure 5a). In addition, the lysosomal activity and mitochon-
drial mass of TRAF-MSCs determined by LysoTracker and
MitoTracker fluorescent dyes, respectively, (mitochondria/
lysosomal fluorescence ratio, 0.8±0.23) was similar to
AF-MSCs (mitochondria/lysosomal fluorescence ratio,
0.78±0.16). However, AL cells and HL cells exhibited
significantly lower ratios of mitochondria/lysosomal fluores-
cence 0.52±0.04 and 0.31±0.04, respectively (Figure 5b ii).
Moreover, semiquantitative PCR analysis revealed that
TRAF-MSCs did not express any of the adipogenic markers,
such as fatty acid-binding protein 4 (FABP4), PPARg and
LPL (Figure 5c i). The hepatogenic marker tyrosine
aminotransferase was expressed in similar levels in
AF-MSCs and TRAF-MSCs (P¼ 0.1087, Student’s t-test),
which implies that later cell types have returned to a more
primitive stem cell-like stage (Figure 5c ii).
Figure 2 Metabolic activity and expression pattern of AF-MSCs, AL cells and DAF-MSCs. (a) Labeled lysosomes (red) and mitochondria (green) in AF-MSCs, AL cells and
DAF-MSCs. (b) MitoTracker/LysoTracker ratios for the three cell types. Data are presented as the mean±S.D. of 10 images per cell category and were statistical analyzed by
one-way ANOVA
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AF-MSCs, DAF-MSCs and TRAF-MSCs exhibit similar
clonogenic potential and proteome profile. AF-, DAF-
and TRAF-MSCs shared similarities in clonogenic potential,
as determined by ‘colony-forming’ unit fibroblast (CFU-F)
assay (Figure 6a). In addition, all three cell types expressed
Oct-4, Sox-2 and Nanog at protein level, as demonstrated by
immunofluorescent staining (Figure 6b). Moreover, we
performed a proteomic analysis of the AF-, DAF- and
TRAF-MSCs, identifying differentially expressed proteins by
2DE gel and MS (Supplementary Figure 3). A comparison of
the expression levels of the respective proteins was
established using PDQuest 8 software (Bio Rad Laboratories
Inc, Hercules, CA, USA). Proteins differentially expressed
41.5-fold (Po0.05, Student’s t-test) in the three populations,
Figure 3 2DE analysis of AF-MSCs, AL cells and DAF-MSCs. (a) Representative 2DE gel image of proteins identified from (i) AF-MSCs, (ii) AL cells and (iii) DAF-MSCs. The
protein spots in each population are indicated with their abbreviated names listed in Supplementary Table 2. (b) Comparative expression analysis for: (i) LEG-1, (ii) PHB, (iii) EIF3I
3 subunit, (iv) VIME, (v) ATPB subunit-b, (vi) RCN3, (vii) PDIA1 and (viii) GSTP1. (c)Western blot analysis in cell extracts from AF-MSCs, AL cells and DAF-MSCs for (i) GSTP1
P1 and (ii) PHB expression. Protein bands of 32 and 26 kDa corresponding to the two above proteins were detected. b-actin was used as positive control for equal loading
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are described in detail in Supplementary Table 2. Specifi-
cally, the metabolic protein Xaa-Pro dipeptidase (PEPD)28
was found to be expressed in high level (5- to 4-fold
expression difference) in AF-MSCs compared with
TRAF-MSCs. Moreover, Rho-GDP-dissociation inhibitor
1 (GDIR1) was expressed in higher levels in DAF-MSCs
and TRAF-MSCs compared with AF-MSCs. GDIR1 is
reported to participate in the process of dedifferentiation of
smooth muscle cells.29 In addition, TRAF-MSCs expressed in
high levels the elongation factor 1-delta (EF1D) and peroxi-
redoxin-4 (PRDX4), both related to differentiation of
MSCs.30,31
To define the differences in the profile of the molecular
mediators secreted by AF-, DAF- and TRAF-MSCs, we
examined the conditioned medium (CM) derived from
AF-MSCs and directly compared this with DAF-MSC-CM and
TRAF-MSC-CM, respectively, using proteome profiler human
arrays (Figure 7a). The array analysis allowed the identification
of 20 secreted growth factors for AF-MSCs, 16 for DAF-MSCs
and 25 for TRAF-MSCs (Supplementary Figure 4).
According to the results obtained, all three cell types
secreted growth factors, which facilitate angiogenesis,
such as angiogenin,32 angiopoietin-1,33 endostatin/collagen
XVIII,34 transforming growth factor-b 1 (TGFb1)35 and
vascular endothelial growth factor (VEGF)19,36 (Figure 7b i).
The Fibroblast growth factor-7 (FGF-7),37 Serpin E1, Serpin
F138 and urinary plasminogen activator (uPA)39 proteins,
responsible for the tissue repair and regeneration, were also
detected in CM derived from AF-, DAF- and TRAF-MSCs
(Figure 7b ii). More importantly, these cells also secreted
Interleukin-8 (IL-8)19,40 and the matrix metalloproteinase-9
(MMP-9),41 which have been suggested as major regulators
of the mobilization of MSCs (Figure 7b iii). Additionally, AF-,
DAF- and TRAF-MSCs secreted factors that have a key role in
cell differentiation, such as insulin-like growth factor-binding
protein 2 (IGFBP-2),42 IGFBP-343 and the tissue inhibitor of
metalloproteinase 1 (TIMP-1)44 (Figure 7b iv, v).
More interestingly, TRAF-MSCs showed higher expression
of TGFb1 and IGFBP-2 molecules, both involved in signaling
pathways related to multiple biological processes, including
Figure 4 Transdifferentiation of AL cells into HL cells. (a) AF-MSCs were induced into AL cells, for 2 weeks in adipogenic medium, and then were transdifferetiated into HL
cells through a dedifferentiation step (TRAF-MSCs). (b) (i) Morphology of AF-MSCs, AL cells, TRAF-MSCs and HL cells, detection of lipid droplets and glycogen storage and
LDL uptake, (ii) quantitation analysis for Oil Red O staining, (iii) PAS staining and (iv) LDL uptake. Data are presented as the mean±S.D., and were statistically analyzed by
one-way ANOVA. Additional statistical analysis pairwise was performed using Student’s t test, (**Po0.01, ***Po0.001)
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cell proliferation, differentiation and also transdifferentiation
through the regulation of specific genes.45,46 Moreover,
TRAF-MSCs secreted Serpin E1, IL-8 and uPA in higher
levels, factors that are increased during the process of
transdifferentiation47–49 and are thought to be stimulated by
the TGFb protein50 (Figure 7b).
It should be mentioned that a number of proteins identified
by proteomic analyses together with the detected secreted
molecules may participate in signaling pathways, by regula-
ting differentiation, angiogenesis and mobilization of MSCs.
In this respect, TGFb, secreted by both AF- and TRAF-
MSCs, is reported to stimulate VIME, a protein detected
in our proteomic analysis, regulating in this way osteo-
blast differentiation51 and TGFb-mediated fibroblastic
transdifferentiation.52 Similarly, HSPB1 was found in high
levels in AF-, DAF- and TRAF-MSCs, and is reported to
Figure 5 Stem cell marker expression and metabolic activity of AF-MSCs, AL cells, TRAF-MSCs and HL cells. (a) Real-time PCR expression analysis for (i) Oct4, (ii) Sox-2
and (iii) Nanog in AF-MSCs, AL, TRAF-MSCs and HL cells. Data are presented as the mean±S.D. of three independent experiments, and the statistical significance was
defined by one-way ANOVA. (b) (i) Microscope photos of labeled lysosomes (red) and mitochondria (green) on AF-MSCs, AL cells, TRAF-MSCs and HL cells. (ii) Ratios of
MitoTracker/LysoTracker for the four cell types. Data are presented as the mean±S.D. of 10 images per cell category, and were statistically analyzed by one-way ANOVA.
(c) Semiquantitative PCR analysis for the expression of (i) the adipogenic markers, FABP4, PPARg and LPL and (ii) the hepatogenic marker, tryrosine aminotransferase in
AF-MSCs, AL, TRAF-MSCs and HL cells. Tyrosine aminotransferase was expressed in similar levels in AF-MSCs and TRAF-MSCs (0.05oPo0.1, Student’s t-test). Data are
presented as the mean±S.D. of three independent experiments and the statistical significance was defined by one-way ANOVA
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interact with the VEGF and to regulate angiogenesis.53 LEG-1
was also detected in the three cell types tested and is involved
in themodulation of JAK/STAT pathway, which is implicated in
HGF and EGF signaling.54
Discussion
Previous studies have shown that adult stem cells, like MSCs,
are able to transdifferentiate from a specific developmental
lineage into another cell type of a different lineage.11,14 Their
cell fate is determined by the expression of several cyto-
kines, growth factors, adhesion molecules and extracellular
matrix components.55 In particular, Tuan and colleagues11
demonstrated that human MSCs derived from the BM (BM-
MSCs), after being differentiated into osteocytes, chondo-
cytes and adipocytes, can transdifferentiate into other cell
types under appropriate culture conditions. This study
proposed that differentiated BM-MSCs dedifferentiate into a
primitive stem cell-like stage before transdifferentiation, likely
through genetic reprogramming. To support their findings, the
same group showed that BM-MSCs, induced to osteogenesis,
adipogenesis or chondrogenesis, could dedifferentiate into a
primitive stem cell-like population, upon the withdrawal of the
stimulating culture medium.14
More recently, human second-trimester AF has been
characterized as a very promising fetal source of MSCs.4–7,13
Figure 6 Clonogenic potential and expression of stem cell markers for AF-, DAF- and TRAF-MSCs. (a) (i, ii) The clonogenic potential of AF-, DAF- and TRAF-MSCs was
determined by CFU-F assay. The mean numbers±S.D. of CFU-F per 100 cells formed in a 14-day clonogenic assay are presented, P valueo0.0107, one-way ANOVA.
(b) Immunofluorescent staining for Oct-4, Sox-2 and Nanog in (i) AF-MSCs, (ii) DAF-MSCs and (iii) TRAF-MSCs. DAPI solution was used for nuclear staining. Original
magnifications,  20
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In our previous studies, we have successfully isolated
and expanded karyotypically normal MSCs from AF and
performed a systematic phenotypic, molecular and proteomic
analysis. The main characteristics of AF-MSCs included the
high number of isolated cells and their rapid expansion in vitro
compared with MSCs from adult sources such as BM-MSCs.7
More importantly, these cells when exposed to appropriate
differentiation culture medium in vitro, showed a multilineage
differentiation potential and ability to overcome the mesoder-
mal commitment by differentiating into hepatocytes.6,7,12
Furthermore, AF-MSCs and their hepatic progenitors induced
liver repair and support liver function by cell transplantation
into acute hepatic failure animal model.6,7,12
In the present study, we used a well-defined cell culture
system to determine whether differentiated AF-MSCs were
able to maintain their plasticity. Specifically, we have shown
that AF-MSCs could successfully differentiate into AL cells
and then these cells, under certain culture conditions, were
able to dedifferentiate and acquire a more primitive pheno-
type. More particularly, we proved that DAF-MSCs expressed
the stem cell markers SSEA-4, Oct-4, Sox-2 and Nanog in
high levels, documenting a similar gene expression profile to
AF-MSCs. Moreover, we studied the lysosomal activity
changes in AF-MSCs during the processes of differentiation
and dedifferentiation. Additionally, we performed a compara-
tive proteomic analysis of AF-MSCs, AL cells and DAF-MSCs,
using 2DE and MS analysis. In particular, 31 proteins were
found to be differentially expressed among the three cell
populations and more interestingly, some of the proteins,
were expressed at the same levels in AF-MSCs and DAF-
MSCs compared with AL cells. These proteins included
VIME, which regulates integrin function, migration and cell
signaling,56 LEG-1, which supports cell differentiation and is
an important stem cell regulatory molecule,57 and PHB, which
promotes cell proliferation and development.23
Moreover, according to our data, precommitted AF-MSCs
to adipogenesis could transdifferentiate into hepatocytes in
response to specific extracellular signals. Thus, the important
question raised was whether differentiated cells into meso-
dermal lineage (AL cells) could transdifferentiate into
endoderm-derived cells (HL cells) directly or through the process
of dedifferentiation. For this reason, AL cells were induced to
hepatogenesis for 21 days before hepatic culture condition
initiation. On the 4th day of transdifferentiation, cells exhibited
similar phenotypic characteristics to AF-MSCs and were termed
as TRAF-MSCs. Interestingly enough, TRAF-MSCs expressed
Figure 7 AF-MSC, DAF-MSC and TRAF-MSC secretome analyses. (a) Representative proteome profile image for growth factors secreted in CM of AF-MSCs, DAF-
MSCs and TRAF-MSCs. (b) Expression levels of growth factors related to (i) angiogenesis, (ii) tissue repair, (iii) mobilization of MSCs, (iv) cell differentiation and (v) apoptosis
in CM of AF-MSCs, DAF-MSCs and TRAF-MSCs. Data presented as mean±S.D. of at least three independent experiments. (c) Corresponding names of each molecule
within the array summarized in tabular form
Plasticity of AF-MSCs
D Zagoura et al
9
Cell Death and Disease
the pluripotency markers Oct-4, Sox-2 and Nanog, implying a
similar gene profile to undifferentiated AF-MSCs, and also
exhibited the same lysosomal activity to AF-MSCs and
maintained their differentiation potential.
In addition, we observed that AF-, DAF- and TRAF-MSCs
displayed similar clonogenic potential and proteome profile as
determined by 2DE gel andMS analysis. We further examined
the secretome of AF-, DAF- and TRAF-MSCs by using a
proteome profile human array. We have concluded that all
three cell types were able to produce molecules, which were
related to angiogenesis, tissue repair and cell differentiation,
documenting the significance of the plasticity of these cells in
tissue regeneration. Moreover, TRAF-MSCs expressed a
number of proteins related to the TGFb1- and IGF signaling
pathways in higher levels compared with AF-MSCs. However,
further studies are needed in order to identify the molecular
mediators that participate in the process of transdifferentiation.
In conclusion, our study has demonstrated that MSCs
derived from AF are capable to dedifferentiate into a more
primitive stem cell type and to transdifferentiate from meso-
derm- to endoderm-derived cells in response to extrinsic
factors, likely through an initial dedifferentiation step, retaining
their multipotentiality. These processes share many similarities
with reprogramming. Similar to the first report of Takahashi and
Yamanaka,58 many different cell types have been repro-
grammed by a combination of exogenous transcription factors.
However, several reports have suggested that dedifferentiation
does not require transcription factors’ introduction, and could
be achieved through specific culture conditions.59
More particularly, a recent study has shown that in vitro
culture could convert epiblast stem cells or progenitor cells from
mouse testis into embryonic stem cell-like cells without the use
of exogenous reprogramming factors, but by specified in vitro
culture conditions.60 More recently, Moschidou et al.15 showed
that stem cells derived from AF can be fully reprogrammed to
pluripotency without genetic manipulation, just in the presence
of human embryonic stem cell medium supplemented with the
valproic acid, a histone deacetylase inhibitor.
Dedifferentiation and transdifferentiation, under specific
culture conditions, could be valuable tools in cell therapy, being
able to generate tissue-specific cells in vitro that can be possibly
used for clinical applications in the future.16 The present study
may support the use of AF-MSCs in future cell-based therapies.
However, the efficient establishment of reprogramming is a
major issue and requires a thorough study.
Materials and Methods
Isolation and culture expansion of AF-MSCs. AF-MSCs were isolated
from six AF samples, collected during scheduled amniocentesis between the 15th
and 18th weeks of gestation, as described previously.6,7 All second-trimester AF
samples were obtained following a written informed consent, approved by the Ethical
Committee of the Alexandra Hospital, Athens and the Bioethics Committee of the
University of Athens, School of Medicine, Athens. Following collection, 10–15ml
from each sample was centrifuged at 1 300 r.p.m. for 10min. The pellet was
resuspended in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich Ltd.,
Gillingham, Dorset, UK) supplemented with 20% (v/v) fetal bovine serum (FBS;
Gibco-BRL, Paisley, Scotland, UK) in a 25-cm2 tissue culture-treated flask and
incubated at 37 1C in a 5% (v/v) humidified CO2 chamber forB20 days, when the
first colonies appeared. Mechanical isolation was performed to isolate the spindle-
shaped (SS) AF-MSCs, according to methods described in our previous studies.6
Cells were used for differentiation at passage 3–5.
Differentiation, dedifferentiation and transdifferentiation of
AF-MSCs. Differentiation of AF-MSCs, DAF-MSCs or TRAF-MSCs into AL,
osteocyte-like (OL) and HL cells was induced. More particularly, to induce
adipogenesis, AF-MSCs or DAF-MSCs, at 1.0–1.3 104/cm2 density were treated
with adipogenic medium, as previously described for 1, 2 or 3 weeks.6,7 For
hepatogenic differentiation, AF-MSCs or DAF-MSCs, at the same density, were
serum-deprived for 2 days. Hepatogenesis was induced by treating AF-MSCs or
DAF-MSCs with differentiation medium, as previously described.6,7,12 To induce
dedifferentiation process, after 2 weeks in culture the adipogenic medium was
removed from the AL cells and it was replaced by AF-MSC medium for 1, 2 and 3
weeks. After 2 weeks in AF-MSC medium, cells exhibited a phenotype similar to
that of AF-MSCs, and were termed as DAF-MSCs (dedifferentiated AF-MSCs).
For transdifferentiation, AF-MSCs were cultured in adipogenic medium for
2 weeks, and then were cultured in hepatogenic medium for further 21 days. After
4 days in culture, cells regained a more primitive phenotype similar to AF-MSCs,
and were termed as TRAF-MSCs. To induce osteogenesis, DAF-MSCs and
TRAF-MSCs were cultured in osteogenic medium for 3 weeks, as described
previously.6,7
Differentiation functional assays. Adipogenesis was determined by
analyzing the lipid formation performing Oil Red O staining (Sigma-Aldrich Ltd.).
Staining was assessed by bright-field microscopy and quantified by the Image
J 1.38x software (Millersville University, Millersville, PA, USA). Quantitative
destaining of Oil Red O staining was performed by adding 1ml of isopropyl alcohol
(Sigma-Aldrich Ltd.) and measuring the absorbance at 500 nm using a
spectrophotometer. The percentage of Oil Red O staining was calculated using
the formula: [(OD day xOD day 0)/OD day 0 100)]. Three independent
experiments were performed, each including three replicates, and the
mean±S.D. of each experiment was calculated.
To analyze hepatogenic differentiation, the cells were assayed for the glycogen
storage, by using a Periodic Acid-Schiff staining system (Sigma-Aldrich). Additionally,
LDL uptake was estimated. Briefly, cells were incubated overnight at 37 1C in a 5% (v/
v) humidified CO2 chamber in DMEM-HG supplemented with 2.5mg/ml Alexa Fluor
488 ACLDL (Molecular Probes Inc.) in the absence of serum. The next day, cells were
examined under a Leica CTR-MIC fluorescent microscope (Buffalo Grove, IL, USA)
and cell fluorescence was analyzed with the Image J 1.38x software.
Osteogenesis was determined by Alizarin Red S (Sigma-Aldrich Ltd.) staining.
Solubilized Alizarin red S was destained by adding 1-ml 10% cetylpyridinium
chloride (Sigma-Aldrich Ltd.), followed by measurement of the absorbance at
570 nm using a spectrophotometer. The percentage of Alizarin red S staining was
calculated using the formula: [(OD day xOD day 0)/OD day 0 100)]. Three
independent experiments were performed, each including three replicates, and the
mean±S.D. of each experiment was calculated.
‘Colony-forming’ unit fibroblast assay. A CFU-F assay was used for
the evaluation of the clonogenic potential of AF-MSCs (passage 5–7), DAF-MSCs
and TRAF-MSCs. CFU-F assay was performed by plating cells at three clonal
densities (70, 140 and 280 cells) in 60-mm plates for 14 days. CFU-Fs were
quantified using Giemsa staining. The number of CFU-Fs was estimated per
100MSCs initially plated, on the basis of the linear regression analysis obtained
from the three different initial cell concentrations.
Antibodies and flow cytometry analysis. AF-MSCs, DAF-MSCs and
AL cells were examined for the expression of SSEA-4 embryonic stem-cell marker
by flow cytometry at different time points. The cells were stained with the antibody
against SSEA-4 (Abcam, Cambridge, UK). As secondary antibody, the
isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (IgG; DAKO
DakoCytomation Ltd, Cambridgeshire, UK) was used. Flow cytometry was
conducted by using Beckman Coulter Cytomics FC 500 flow cytometer (Beckman
Coulter Ltd, Palo Alto, CA, USA).
Immunofluorescent staining. For immunofluorescent staining, cells were
permeabilized in 0.1% (v/v) Triton-X (Sigma-Aldrich), supplemented with 5% donkey
serum (Sigma-Aldrich) for 30min at room temperature after fixation in
4% paraformaldehyde (Sigma-Aldrich). Cells were then stained with rabbit anti-human
Oct-3/4 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), rabbit anti-human
Nanog (Abcam) or rabbit anti-human Sox-2 (Millipore, Hayward, CA, USA)
antibodies. The latter reactions were developed with Alexa-488-conjugated goat
anti-rabbit (Invitrogen Ltd., Grand Island, NY USA) secondary antibody. Slides were
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mounted with vectashield mounting medium (Vector Laboratories Inc., Burlingame,
CA, USA) containing DAPI solution. Cells were visualized and photographed on a
Leica CTR-MIC Fluorescent microscope.
Mitochondria and lysosomal fluorescent measurement. Mito-
Tracker Green FM and LysoTracker Red (Molecular Probes Inc) were diluted in
DMEM to the appropriate concentrations. Cells were incubated with prewarmed
(37 1C) probe-containing medium for 1 h for LysoTracker Red and for 45min for
MitoTracker Green FM. Cells were visualized and photographed on a Leica CTR-
MIC Fluorescent microscope. All images were analyzed with Image J 1.38x
software and the ratio of MitoTracker/LysoTracker was calculated for each sample
(AF-MSCs, DAF-MSCs, TRAF-MSCs, AL cells and HL cells). Ten different areas
from each image were used for statistical analysis.
RT-PCR procedure and semiquantitative PCR. Total RNA was
extracted from the cells using the Tri Reagent (Sigma-Aldrich), according to the
manufacturer’s instructions. The mRNA was reverse transcribed to cDNA using
the M-MLV Reverse Transcriptase-RNase H Minus kit (Promega, Madison, WI,
USA). Subsequent PCR reactions were performed using cDNA, primer pairs and
Go Taq Green master mix, (Promega). Semiquantitative PCR analysis was
determined by using the Image J 1.38x software after normalization to the b-actin
endogenous control. The primers used are listed in Supplementary Table 1.
Real-time quantitative PCR. Real-time quantitative PCR was conducted
on an ABI Prism 7000 apparatus (Applied Biosystems, Foster City, CA, USA).
Each cDNA sample was mixed with specific primer sets and PCR master mix
(Applied Biosystems, No. 4312704). TaqMan real-time PCR was used for Oct-4,
Sox-2 and Nanog gene expression analysis with primers and conditions
designated by Assays on Demand, Gene Expression Products (Applied
Biosystems Hs00742896_s1 (oct-4), Hs01053049_s1 9 (sox-2), Hs02387400_s1
(Nanog), respectively). Analysis was performed by using the ABI Prism 7700 SDS
software (Applied Biosystems). The expression of Oct-4, Sox-2 and Nanog was
normalized to GAPDH internal control (GAPDH, TaqMan pre-developed assay
reagents, Applied Biosystems, No. 433764T). Data were analyzed by the relative
quantification (DDCt) method, as described in our previous studies.6,7 Then, the
relative level of Oct-4, Sox-2 or Nanog in AF-MSCs was compared with DAF-
MSCs, TRAF-MSCs, AL cells or HL cells by setting the AF-MSCs gene expression
value to 1 and determining the fold change in expression against this value, using
the following formula: 2DDCt. Quantitative real-time PCR was carried out for
PPARg, FABP4, Runx2, osteocalcin, tyrosine aminotransferase and AFP using
SYBR Green PCR master mix, according to the manufacturer’s protocol (Applied
Biosystems) and appropriate primers (Invitrogen Ltd.). b-actin was used as the
internal control. The primers used are listed in Supplementary Table 1.
Proteomic analysis. At least three biological samples of the four categories
(AF-MSCs, AL cells, DAF-MSCs and TRAF-MSCs) were analyzed by 2DE in
triplicates, as was described previously.7 The protein identification was based on
specific criteria, which included a maximum allowed mass error of 25 p.p.m. and a
minimum of five matching peptides. More particularly, a high percentage of the
proteins were identified based on 10 matches and the probability of a false identity
was usually lower than 10 5. Finally, the functional properties of the identified
proteins were analyzed by the Swiss-Prot (http://www.expasy.org/sprot) and
Human Protein Reference Databases (http://www.hprd.org). Protein expression
was calculated (in p.p.m.) by using the PD Quest 8 software package (Bio Rad
Laboratories Inc.), and is shown as a ratio of the intensity of protein spots in AF-
MSCs to AL cells, AF-MSCs to DAF-MSCs, DAF-MSCs to AL cells, AF-MSCs to
TRAF-MSCs or DAF-MSCs to TRAF-MSCs. Comparison of the expression level of
the various protein spots was conducted by the use of Student’s t-test. In all
cases, Po0.05 was considered statistically significant.
Western blot. Total protein extracts of AF-MSCs, AL cells and DAF-MSCs
were separated by 10% SDS-PAGE under reducing conditions and electroblotted
to Hybond-ECL NC membrane (Amersham Biosciences, Uppsala, Sweden). After
blocking, membranes were incubated overnight at 4 1C with the primary
antibodies: mouse anti-human PHB (Santa Cruz Biotechnology Inc.) and mouse
anti-human GSTP1 (Santa Cruz Biotechnology Inc.). Mouse anti-human b-actin
antibody (Sigma Aldrich, Ltd.) was used as a control of equal loading. Membranes
were then incubated with anti-mouse HRP-conjugated secondary antibody (Santa
Cruz Biotechnology Inc.) and developed by ECL (PerkinElmer, Waltham, MA,
USA) detection system. Films were scanned and images were analyzed using
Quantity One software 4.4.1 (Bio Rad Laboratories Inc.).
Proteome array of AF-MSCs, DAF-MSCs and TRAF-MSCs. For
the preparation of the CM, 1 106 AF-, DAF- or TRAF-MSCs were cultured until
80% confluent in their respective media, and then the media were replaced with
DMEM containing 0.5% (v/v) FBS to prevent protein aggregation. The cells were
cultured for further 24 h and the CM was collected and concentrated B10-fold
using ultra filtration units with a 3-kDa cut-off (Millipore, Bedford, MA, USA). The
analysis for specific proteins was performed using proteome profiler human arrays
(Catalog No. ARY007, R&D Systems Inc., Minneapolis, MN, USA), according to
the manufacturer’s instructions. Quantitation of the detected spots was performed
using the Quantity One Software 4.4.1 (Bio Rad Laboratories Inc). Values were
normalized to positive controls. Data are presented as the mean±S.D. for three
independent experiments.
Statistical analysis. Statistical analysis was performed using GraphPad
Prism IV software (GraphPad Software Inc., La Jolla, CA, USA). One-way ANOVA
(Kruskal—Wallis) was used to analyze the statistical significance of data from
different experimental groups. In all cases, P value of o0.05 was considered
significant. Statistical analysis pairwise was performed using Student’s t test,
(*Po0.05) when applicable.
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